Long-term Documentation of the Utilization of Otezla in Patients With Plaque Psoriasis Under Routine Conditions (LAPIS-Pso)
Phase of Trial: Phase IV
Latest Information Update: 24 May 2017
At a glance
- Drugs Apremilast (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Acronyms LAPIS-Pso
- Sponsors Celgene Corporation
- 03 Mar 2017 According to a Celgene Corporation media release, data from this trial will be presented at the 75th Annual Meeting of the American Academy of Dermatology (AAD).
- 19 Sep 2016 Planned End Date changed from 1 Jul 2017 to 1 Dec 2017.
- 11 Dec 2015 New trial record